Every prescriber is a competitor now
Before 2023, prescribing buprenorphine required the DATA-Waiver, and the list of waivered prescribers in a county was short enough to memorize. Congress removed that requirement and the constraint on supply went with it. Family medicine practices added it. Urgent cares added it. Telehealth companies with national ad budgets added it everywhere at once.
Demand did not grow at the same rate. So a clinic that used to rank by default now competes against practices with no addiction specialty at all and a faster intake.
The advantage a real MAT program still holds is depth: counseling, case management, same-day starts, on-site dosing, wraparound services. None of it is visible in a search result until somebody writes it down on the page.
Medicaid economics change what a patient is worth
A residential program can spend thousands to acquire one admission because the episode bills at tens of thousands. A MAT clinic billing Medicaid for an office visit and a monthly prescription cannot. On a per-visit basis the numbers do not work.
They work over time. A retained MAT patient comes back every week, then every two weeks, then monthly, for months or years. The value is in retention, so acquisition has to be measured at day 30 and day 90 rather than at the first appointment.
This is where most MAT reporting falls apart. The agency reports new patient calls. Nobody reports how many of those patients came back a second time. A channel producing cheap first visits and 20% thirty-day retention costs more than one producing expensive first visits that stick.